2026-04-27T11:48:11Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/109202025-10-04T00:05:21Zcom_10259_4862com_10259_5086com_10259_2604col_10259_4863

Chromikova, Veronika 71f494a1-3d73-4ed6-a641-8fa0da5ff3ed 500 Tan, Jessica 5853bb90-57e0-4f5e-85e8-ec3fbf823964 500 Aslam, Sadaf 34ce451c-1783-43a0-99fe-d911a3c31bcd 500 Rajabhathor, Arvind c0600618-2a11-40b7-98eb-0643e09e9500 500 Bermudez-Gonzalez, Maria 91d1bf90-5f74-4d21-a6c5-42e7e5592543 600 Ayllón Barasoain, Juan 852 600 0000-0002-7556-8106 Simon, Viviana 0829d844-d5f4-4b61-857c-f6c94ddd4c6d 600 García Sastre, Adolfo 9de2ea8b-c019-414d-bb90-b1d51ef5bbd7 600 Salaun, Bruno 615b880b-1f8d-4dbc-96df-228ffc5c3557 500 Nachbagauer, Raffael 82324927-4a7b-40f4-a5b8-87a5e7f9a35a 500 Krammer, Florian 134d72a4-c1a0-45c7-97bf-f4dc99569766 500 2025-10-03T11:16:48Z 2025-10-03T11:16:48Z 2020-02 0264-410X https://hdl.handle.net/10259/10920 10.1016/j.vaccine.2020.01.008 1873-2518 The stalk of the influenza virus hemagglutinin (HA) is an attractive target for antibody-based universal influenza virus vaccine development. While antibodies that target this part of the virus can be neutralizing, it has been shown in recent years that Fc receptor-mediated effector functions are of significant importance for the protective effect of anti-stalk antibodies. Several assays to measure Fc-Fc receptor interaction-based effector functions like antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis exist, but they suffer from limitations such as low throughput and high run-to-run variability. Reporter assays for antibody-dependent cellular cytotoxicity based on reporter cells that express luciferase upon engagement of human FcγRIIIa with the Fc of antigen-bound antibodies have been developed as well. These reporter assays can be used in a higher throughput setting with limited run-to-run assay variability but since they express only one Fc receptor, their biological relevance is unclear. Here we optimized an antibody-dependent cellular cytotoxicity reporter assay to measure the activity of antibodies to the conserved stalk domain of H1 hemagglutinin. The assay was then correlated to a CD107a-based degranulation assay, and a strong and significant correlation could be observed. This data suggests that the FcγRIIIa-based reporter assay is a good substitute for functional assays, especially in settings where larger sample numbers need to be analyzed. Work in the Krammer laboratory was supported by GlaxoSmithKline as well as funding from the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS, HHSN272201400008C). We would like to thank Dr. Patrick Wilson from the University of Chicago for providing plasmids for human mAb expression, the Icahn School of Medicine Flow Cytometry Core for access to the flow cytometers and Dr. Evren Azeloglu for assistance with fluorescence microscopy. We would also like to thank Elena Hirsch for expert sample processing as well as the study participants. application/pdf eng Elsevier Vaccine. 2020, V. 8, n. 38, p.1953–1961 https://doi.org/10.1016/j.vaccine.2020.01.008 Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Influenza hemagglutinin ADCC ADCP Effector functions Stalk antibodies Seroterapia Serotherapy Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion Vaccine 38 8 1953 1961 THUMBNAIL Chromikova_Vaccine_2020.pdf.jpg Chromikova_Vaccine_2020.pdf.jpg IM Thumbnail image/jpeg 4830 https://riubu.ubu.es/bitstream/10259/10920/5/Chromikova_Vaccine_2020.pdf.jpg 8057693e150db7285ec8bbd0393594b9 MD5 5 LICENSE license.txt license.txt text/plain; charset=utf-8 999 https://riubu.ubu.es/bitstream/10259/10920/3/license.txt b295bcbce42e2caabeb0c623d3860c06 MD5 3 CC-LICENSE license_rdf license_rdf application/rdf+xml; charset=utf-8 805 https://riubu.ubu.es/bitstream/10259/10920/2/license_rdf 4460e5956bc1d1639be9ae6146a50347 MD5 2 ORIGINAL Chromikova_Vaccine_2020.pdf Chromikova_Vaccine_2020.pdf application/pdf 1340741 https://riubu.ubu.es/bitstream/10259/10920/4/Chromikova_Vaccine_2020.pdf ebae8de152e530e2779542141935c6b7 MD5 4 10259/10920 oai:riubu.ubu.es:10259/10920 2025-10-04 02:05:21.117 Repositorio Institucional de la Universidad de Burgos bubrep@ubu.es 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